InvestorQ : Is Jubilant Life Sciences worth buying at current prices after the latest quarter results?
Priyanka N made post

Is Jubilant Life Sciences worth buying at current prices after the latest quarter results?

Answer
user profile image
NISHA Nayak answered.
5 months ago


Jubilant Life Sciences, part of the Bhartia group, reported net profits of Rs.260.49 crore for the quarter ended on 31 March 2020, driven by robust sales in the pharma segment. Revenues from operations in the Mar-20 quarter were flat at Rs.2391 crore. For the fiscal year 2019-20, Jubilant Life reported net profits of Rs.898 crore against Rs.577 crore in the corresponding quarter last year. The profit was driven by 58% growth in EBITDA for the March quarter. Jubilant is one of the Indian companies to receive the license to manufacture Remdesivir tablets to cure COVID-19 under license agreement with Gilead Inc of the United States.